膀胱活动低下症的治疗进展  

Progress in the treatment of underactive bladder

作　　者：黄涛 罗振恺[1,2] 矫宾宾 孙海燕 张冠 任建(审校)[2] HUANG Tao;LUO Zhenkai;IAO Binbin;SUN Haiyan;ZHANG Guan;REN Jian(China-Japan Friendship College of Clinical Medicine,Peking University,Beijin,100029,China;Department of Urology,China-Japan Friend ship Hospital;Peking Union Medical College,Chinese Academy of Medical Sciences)

机构地区：[1]北京大学中日友好临床医学院,北京100029 [2]中日友好医院泌尿外科 [3]中国医学科学院北京协和医学院

出　　处：《临床泌尿外科杂志》2021年第2期157-163,共7页Journal of Clinical Urology

摘　　要：膀胱活动低下症(UAB)是膀胱功能障碍的一种常见类型,由于人们对其认识较为局限,UAB的治疗措施仍缺乏统一标准。UAB的治疗旨在减少残余尿量、避免膀胱过度充盈,预防上尿路损伤。药物治疗如拟副交感神经药或α-受体阻滞剂的疗效与安全性存在争议。膀胱出口手术,包括经尿道膀胱颈切开术和经尿道前列腺电切术等,可以有效改善患者的尿流率并减少残余尿量。骶神经调节(SNM)经美国食品和药品管理局批准用于治疗非梗阻性尿潴留。此外,干细胞疗法和基因治疗等新的治疗措施也在探索之中。Underactive bladder(UAB) is a common type of bladder dysfunction. The treatment measures of UAB still lack consensus due to the limited understanding of its etiopathogenesis. UAB treatments are aimed at reducing postvoid residual(PVR), avoiding overfilling the bladder and preventing upper urinary tract damage. The efficacy and safety of medications such as parasympathomimetics or alpha-blockers are controversial. Bladder outlet surgeries, including transurethral bladder neck incision and transurethral resection of prostate can effectively improve the urination efficiency and reduce PVR. Sacral neuromodulation(SNM) is approved by the US Food and Drug Administration for non-obstructive urinary retention. In addition, new treatments such as stem cell and gene therapy are also being explored.

关 键 词：膀胱功能障碍 膀胱活动低下 治疗 

分 类 号：R694[医药卫生—泌尿科学]